Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M. Kiyota N, et al. Among authors: shimizu y. Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1. Oral Oncol. 2017. PMID: 28939066 Free article. Clinical Trial.
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Mizumachi T, Homma A, Kakizaki T, Sakashita T, Kano S, Hatakeyama H, Tsuchiya K, Yasuda K, Onimaru R, Shirato H, Taguchi J, Shimizu Y, Kinoshita I, Akita H, Fukuda S. Mizumachi T, et al. Among authors: shimizu y. Int J Clin Oncol. 2015 Jun;20(3):431-7. doi: 10.1007/s10147-014-0726-y. Epub 2014 Jul 5. Int J Clin Oncol. 2015. PMID: 24993675 Free article.
A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition).
Head and Neck Cancer Study Group (HNCSG); Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N, Kodaira T, Zenda S, Fujii H, Tahara M, Yokota T, Akimoto T, Iwae S, Onitsuka T, Ogawa T, Okano S, Takahashi S, Shimizu Y, Yonezawa K, Hayashi R. Head and Neck Cancer Study Group (HNCSG), et al. Among authors: shimizu y. Jpn J Clin Oncol. 2019 Jul 1;49(7):589-595. doi: 10.1093/jjco/hyz052. Jpn J Clin Oncol. 2019. PMID: 31194232 Review.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T, Ogawa T, Homma A, Okami K, Minami S, Nakanome A, Shimizu Y, Maki D, Ueda Y, Fujisawa T, Motegi A, Ohkoshi A, Taguchi J, Ebisumoto K, Nomura S, Okano S, Tahara M. Enokida T, et al. Among authors: shimizu y. Cancer Med. 2020 Mar;9(5):1671-1682. doi: 10.1002/cam4.2852. Epub 2020 Jan 13. Cancer Med. 2020. PMID: 31943834 Free PMC article. Clinical Trial.
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Yen CJ, et al. Among authors: shimizu y. Head Neck. 2020 Oct;42(10):2852-2862. doi: 10.1002/hed.26331. Epub 2020 Jun 24. Head Neck. 2020. PMID: 32583557 Free PMC article. Clinical Trial.
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A, Dosaka-Akita H. Taguchi J, et al. Among authors: shimizu y. Int J Clin Oncol. 2021 Jan;26(1):51-58. doi: 10.1007/s10147-020-01788-6. Epub 2020 Sep 29. Int J Clin Oncol. 2021. PMID: 32996023 Clinical Trial.
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study.
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A. Hanai N, et al. Among authors: shimizu y. Int J Clin Oncol. 2021 Mar;26(3):494-506. doi: 10.1007/s10147-020-01829-0. Epub 2020 Nov 21. Int J Clin Oncol. 2021. PMID: 33219460 Free PMC article.
6,165 results